CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.51B, above the global median of $1.15B
- PositionPrice-to-book is 1.25×, lower than 95% of its Biotechnology peers (median 5.36×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
10.15BCNY1.51B · vs all stocks (USD)
Trailing P/E
28.86xvs Biotechnology peers
Revenue (TTM)
2.60BCNY385.71M · vs all stocks (USD)
Profit Margin
13.58%vs Biotechnology peers
Beta
0.4510xvs all stocks
52-Week Change
-40.47%vs all stocks
Market Capitalization
10.15BCNY1.51B · vs all stocks (USD)
Enterprise Value
10.43BCNY1.55B · vs all stocks (USD)
Trailing P/E
28.86xvs Biotechnology peers
Forward P/E
9.99xvs Biotechnology peers
PEG Ratio
-0.3685xvs Biotechnology peers
Price to Sales (TTM)
3.90xvs Biotechnology peers
Price to Book (MRQ)
1.25xvs Biotechnology peers
Enterprise to Revenue
4.01xvs Biotechnology peers
Enterprise to EBITDA
16.75xvs Biotechnology peers
Gross Margin
34.82%vs Biotechnology peers
Profit Margin
13.58%vs Biotechnology peers
Operating Margin
6.08%vs Biotechnology peers
Return on Assets (TTM)
3.29%vs Biotechnology peers
Return on Equity (TTM)
4.39%vs Biotechnology peers
Revenue (TTM)
2.60BCNY385.71M · vs all stocks (USD)
Revenue per Share (TTM)
2.62CNYUpdated Aug 18, 2026Quarterly Revenue Growth
-8.50%vs Biotechnology peers
Gross Profit (TTM)
1.03BCNY152.52M · vs all stocks (USD)
EBITDA (TTM)
552.47MCNY81.93M · vs all stocks (USD)
Net Income (TTM)
353.15MCNY52.37M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-74.20%vs Biotechnology peers
Operating Cash Flow (TTM)
-272.00MCNY-40.34M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-672.01MCNY-99.66M · vs all stocks (USD)
Payout Ratio
72.76%vs Biotechnology peers
Minority Interest (Equity)
-6.78MCNYFY2025 · Dec 31, 2025Revenue
2.63BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.54BCNYFY2025 · Dec 31, 2025Gross Profit
1.09BCNYFY2025 · Dec 31, 2025Operating Income
586.54MCNY86.98M · vs all stocks (USD)
Pre-tax Income
500.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
80.77MCNYFY2025 · Dec 31, 2025Net Income
419.54MCNYFY2025 · Dec 31, 2025EBIT
518.49MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
764.98MCNYFY2025 · Dec 31, 2025Research & Development
55.92MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
287.63MCNYFY2025 · Dec 31, 2025Other Operating Expenses
22.26MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
54.57MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
18.19MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.4400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.4400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
952.88MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
952.88MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
419.54MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-269.57KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-406.49MCNYFY2025 · Dec 31, 2025Free Cash Flow
-739.40MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
769.60MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
419.54MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-23.54MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-472.67MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-329.81MCNYFY2025 · Dec 31, 2025Capital Expenditures
-332.91MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.45BCNYFY2025 · Dec 31, 2025Sale of Investments
1.50BCNYFY2025 · Dec 31, 2025Other Investing Activity
54.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-231.32MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
771.21MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-595.31MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-273.80MCNYFY2025 · Dec 31, 2025Other Financing Charges
-5.60MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-103.51MCNYFY2025 · Dec 31, 2025Shares Outstanding
950.40MSharesUpdated Aug 18, 2026Float Shares
532.55MSharesUpdated Aug 18, 2026% Held by Insiders
44.56%vs all stocks
% Held by Institutions
6.39%vs all stocks
Total Cash (MRQ)
699.24MCNY103.70M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7360CNYUpdated Aug 18, 2026Total Debt (MRQ)
787.09MCNY116.73M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0971xvs Biotechnology peers
Current Ratio (MRQ)
3.37xvs Biotechnology peers
Book Value per Share (MRQ)
8.53CNYUpdated Aug 18, 2026Total Assets
9.47BCNY1.40B · vs all stocks (USD)
Total Current Assets
3.72BCNYFY2025 · Dec 31, 2025Total Liabilities
1.39BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.75BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
256.62MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.13BCNYFY2025 · Dec 31, 2025Cash
763.41MCNYFY2025 · Dec 31, 2025Cash Equivalents
6.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
770.16MCNYFY2025 · Dec 31, 2025Other Short-term Investments
254.39MCNYFY2025 · Dec 31, 2025Accounts Receivable
929.58MCNYFY2025 · Dec 31, 2025Inventory
1.56BCNYFY2025 · Dec 31, 2025Accounts Payable
155.26MCNYFY2025 · Dec 31, 2025Short-term Debt
607.30MCNYFY2025 · Dec 31, 2025Other Current Liabilities
18.86MCNYFY2025 · Dec 31, 2025Long-term Debt
205.77MCNYFY2025 · Dec 31, 2025Common Stock (Book)
950.40MCNYFY2025 · Dec 31, 2025Retained Earnings
2.42BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
8.08BCNY1.20B · vs all stocks (USD)
52-Week Low
8.54CNYUpdated Aug 18, 202652-Week High
18.52CNYUpdated Aug 18, 202652-Week Change
-40.47%vs all stocks
Beta
0.4510xvs all stocks
50-Day MA
10.17CNYUpdated Aug 18, 2026200-Day MA
12.72CNYUpdated Aug 18, 2026Avg 10-Day Volume
13.32MSharesUpdated Aug 18, 2026Avg 30-Day Volume
13.39MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
0.3700CNYUpdated Aug 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 1.25×, lower than 95% of its Biotechnology peers (median 5.36×)Notable
Price-to-book: 1.25Industry median: 5.36Industry P5: 1.40Peers compared: 197
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 52,371,549.427Operating Cash Flow (USD, TTM): -40,338,017.613
Financial Health
Altman Z-Score 5.54: safe zoneNotable
Altman Z-Score: 5.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.51B, above the global median of $1.15BNotable
Market cap (USD): 1,505,281,197.361Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Traditional Chinese Medicine Holdings Co. Limited
Tier 1ProductionApproval-Gated PipelineFlowInterface
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule